July 2022 "Not even a PIPE financing could save X4 Pharmaceuticals from enacting layoffs and trimming The move comes less than three weeks after X4 pulled together a $55 million PIPE and amended a loan facility

Therapeutics To Release Half-Year 2023 Financial Results And Host Conference Call On August 10, 2023 X4 Pharmaceuticals Closes $115 Million Loan Facility with Hercules Capital Gene-to-structure and Europe adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results And Provides Corporate Update X4 Pharmaceuticals Announces

Industry News X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market Andrew

develop new therapies for people living with obesity, diabetes and other serious metabolic diseases X4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results, Provides Corporate Updates, and Reports

GPCR–Gαs–PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure Industry News X4 Pharmaceuticals Expected to Join Russell 3000® Index.

Multi-Product Pipeline Toward Clinical Studies Confo Therapeutics Appoints Dieter Weinand, Former CEO Of Bayer Pharmaceuticals Wainwright 25th Annual Global Investment Conference X4 Pharmaceuticals to Participate in the Morgan Stanley

Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage X4 Pharmaceuticals Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and

April 2022 "SAN DIEGO, April 12, 2022 — Crinetics Pharmaceuticals , Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization

December 2021 Crinetics Pharmaceuticals announced the formation of an independently operated new company and Crinetics to Collaborate on Multiple Additional targets SAN DIEGO, October 18, 2021 — Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization

March 2022 Crinetics Pharmaceuticals Expands Executive Team With Appointment Of James Hassard As Chief Commercial Officer "SAN DIEGO – March 1, 2022 – Crinetics Pharmaceuticals , Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization

April 2022 Design Pharmaceuticals Closes $5 Million Pre-series A Round to Accelerate Commercialization Throughput Drug Discovery Platform " April 12, 2022 07:00 AM Eastern Daylight Time CAMBRIDGE, Mass.-- Design Pharmaceuticals Design Pharmaceuticals ’ platform is based on ultrahigh-throughput technologies that biomine drug-like

November 2021 Addex's strategic partner The Janssen Pharmaceutical Companies of Johnson & Johnson, Inc Switzerland, November 15, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical pioneering allosteric modulation-based drug discovery and development, today announced that Janssen Pharmaceuticals , Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson , has successfully completed

June 2022 "CRN04894 Selected for Oral Presentation SAN DIEGO, June 8, 2022 — Crinetics Pharmaceuticals

Trevena Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical The NDA was submitted by Trevena’s partner, Jiangsu Nhwa Pharmaceutical, and follows completion by Nhwa

Domain Therapeutics and Université de Montréal for GPCR-Targeted Drug Discovery " Apr.19.2022 　 Ono Pharmaceutical

monoclonalantibodies #drugdiscovery #biotechnology #research #ionchannels #biologics #biotech #pharma #pharmaindustry #pharmaceuticals

- 4, 2024 | Chemotactic Cytokines GPCR Jobs NEW Senior Scientist, In vitro pharmacology - Crinetics Pharmaceuticals NEW Senior Director, In vitro pharmacology - Crinetics Pharmaceuticals In vivo Antibody Discovery Research

Geneva, Switzerland, March 7, 2022 – Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical

Jobs NEW Head of Human Resource Business Partners Senior Scientist, In vitro pharmacology - Crinetics Pharmaceuticals Senior Director, In vitro pharmacology - Crinetics Pharmaceuticals In vivo Antibody Discovery Research

Apprentice Head of Human Resource Business Partners Senior Scientist, In vitro pharmacology - Crinetics Pharmaceuticals Senior Director, In vitro pharmacology - Crinetics Pharmaceuticals In vivo Antibody Discovery Research

research in biomedical sciences with the mechanistic understanding of one of the biggest classes of pharmaceutical

Geneva, Switzerland, August 18, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical

recently had the pleasure of speaking with Beth Fleck, Director of In Vitro Pharmacology at Crinetics Pharmaceuticals

, Switzerland, April 13, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical

Geneva, Switzerland, April 6, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical

GPCR Jobs Head of Human Resource Business Partners Senior Scientist, In vitro pharmacology - Crinetics Pharmaceuticals Senior Director, In vitro pharmacology - Crinetics Pharmaceuticals In vivo Antibody Discovery Research

Confo Therapeutics today announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals

Geneva, Switzerland, August 15, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical